103 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
4 Nov 22
Other Events
11:24am
) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy … .
In 2023 Processa plans to begin enrolling patients into the Phase 2B trial to identify the regimens that improve the efficacy-safety profile over
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
25 Jan 24
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
8:35am
Exhibit 99.1
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer … pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
19 Dec 23
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
9:00am
Exhibit 99.1
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety … -FU
Interim analysis of the NGC-Cap Phase 1b data shows improved safety, even with 5-FU exposure much greater than that from capecitabine
Company
8-K
EX-99.1
u3zqls j6i
18 May 23
Regulation FD Disclosure
3:24pm
8-K
EX-99.1
nmgsnys q9ibsigumuj
19 Jan 24
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
8:00am
8-K
p2i0b3m9fg4rt gy72p
19 Dec 23
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
9:00am
8-K
a3qr06
25 Jan 24
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
8:35am
8-K
EX-99.1
1agqzyiz 2dm
17 Mar 20
Processa Pharmaceuticals Announces Results from the Phase 2 Study In Necrobiosis Lipoidica
9:30am
8-K
cyr rp1pgm24lrnvayp
12 Oct 17
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
77lex1xobm
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
8-K
EX-99.1
nbbuzvk58
31 Mar 23
Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
8:30am